Alison M Mondul1, Stephanie J Weinstein, Jarmo Virtamo, Demetrius Albanes. 1. Department of Health and Human Services, Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, 6120 Executive Blvd., Rockville, MD 20852, USA. mondulam@mail.nih.gov
Abstract
BACKGROUND: Studies suggest a decreased risk of high-grade prostate cancer in men with lower circulating total cholesterol and that statins may protect against aggressive disease. Confirmation in additional populations and examination of associations for lipoprotein subfractions are needed. METHODS: We examined prostate cancer risk and serum total and HDL cholesterol in the ATBC Study cohort (n = 29,093). Cox proportional hazards models were used to estimate the relative risk of total (n = 2,041), non-aggressive (n = 829), aggressive (n = 461), advanced (n = 412), and high-grade (n = 231) prostate cancer by categories of total and HDL cholesterol. RESULTS: After excluding the first 10 years of follow-up, men with higher serum total cholesterol were at increased risk of overall (≥240 vs. <200 mg/dl: HR = 1.22, 95% CI 1.03-1.44, p-trend = 0.01) and advanced (≥240 vs. <200 mg/dl: HR = 1.85, 95% CI 1.13-3.03, p-trend = 0.05) prostate cancer. Higher HDL cholesterol was suggestively associated with a decreased risk of prostate cancer regardless of stage or grade. CONCLUSIONS: In this population of smokers, high serum total cholesterol was associated with higher risk of advanced prostate cancer, and high HDL cholesterol suggestively reduced the risk of prostate cancer overall. These results support previous studies and, indirectly, support the hypothesis that statins may reduce the risk of advanced prostate cancer by lowering cholesterol.
RCT Entities:
BACKGROUND: Studies suggest a decreased risk of high-grade prostate cancer in men with lower circulating total cholesterol and that statins may protect against aggressive disease. Confirmation in additional populations and examination of associations for lipoprotein subfractions are needed. METHODS: We examined prostate cancer risk and serum total and HDL cholesterol in the ATBC Study cohort (n = 29,093). Cox proportional hazards models were used to estimate the relative risk of total (n = 2,041), non-aggressive (n = 829), aggressive (n = 461), advanced (n = 412), and high-grade (n = 231) prostate cancer by categories of total and HDL cholesterol. RESULTS: After excluding the first 10 years of follow-up, men with higher serum total cholesterol were at increased risk of overall (≥240 vs. <200 mg/dl: HR = 1.22, 95% CI 1.03-1.44, p-trend = 0.01) and advanced (≥240 vs. <200 mg/dl: HR = 1.85, 95% CI 1.13-3.03, p-trend = 0.05) prostate cancer. Higher HDL cholesterol was suggestively associated with a decreased risk of prostate cancer regardless of stage or grade. CONCLUSIONS: In this population of smokers, high serum total cholesterol was associated with higher risk of advanced prostate cancer, and high HDL cholesterol suggestively reduced the risk of prostate cancer overall. These results support previous studies and, indirectly, support the hypothesis that statins may reduce the risk of advanced prostate cancer by lowering cholesterol.
Authors: Mieke Van Hemelrijck; Göran Walldius; Ingmar Jungner; Niklas Hammar; Hans Garmo; Elisa Binda; Adrian Hayday; Mats Lambe; Lars Holmberg Journal: Cancer Causes Control Date: 2011-05-12 Impact factor: 2.506
Authors: Melissa A Babcook; Sanjeev Shukla; Pingfu Fu; Edwin J Vazquez; Michelle A Puchowicz; Joseph P Molter; Christine Z Oak; Gregory T MacLennan; Chris A Flask; Daniel J Lindner; Yvonne Parker; Firouz Daneshgari; Sanjay Gupta Journal: Mol Cancer Ther Date: 2014-08-13 Impact factor: 6.261
Authors: Mahmoud A Alfaqih; Erik R Nelson; Wen Liu; Rachid Safi; Jeffery S Jasper; Everardo Macias; Joseph Geradts; J Will Thompson; Laura G Dubois; Michael R Freeman; Ching-Yi Chang; Jen-Tsan Chi; Donald P McDonnell; Stephen J Freedland Journal: Cancer Res Date: 2017-01-27 Impact factor: 12.701
Authors: Elizabeth M Masko; Mahmoud A Alfaqih; Keith R Solomon; William T Barry; Christopher B Newgard; Michael J Muehlbauer; Nikolaos A Valilis; Tameika E Phillips; Susan H Poulton; Alexis R Freedland; Stephanie Sun; Shweta K Dambal; Sergio E Sanders; Everardo Macias; Michael R Freeman; Mark W Dewhirst; Salvatore V Pizzo; Stephen J Freedland Journal: Prostate Date: 2016-11-30 Impact factor: 4.104
Authors: K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano Journal: J Endocrinol Invest Date: 2013-02 Impact factor: 4.256
Authors: Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro Journal: Am J Cancer Res Date: 2013-01-18 Impact factor: 6.166